Navigation Links
ThromCat(R) XT(TM) Thrombectomy Catheter System Receives CE Mark
Date:6/23/2009

- KENSEY NASH EARNS $1.5M MILESTONE UNDER SPECTRANETICS AGREEMENT -

EXTON, Pa., June 23 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that the ThromCat(R) XT Thrombectomy Catheter System has been granted CE Marking approval which allows for the sale of the product throughout the European Economic Area (EEA). The ThromCat XT System, a mechanical thrombectomy catheter designed to remove thrombus (blood clots) from a patient, is indicated for use in both the coronary and peripheral vasculature. The CE Mark approval meets the criteria established for a milestone payment of $1.5 million under the Company's Development and Regulatory Services Agreement with The Spectranetics Corporation (Spectranetics). The milestone payment to Kensey Nash Corporation will be recorded as deferred revenue and will be recognized into revenue over the remaining period of the Agreement.

"We are pleased to announce the achievement of this important milestone and to provide Spectranetics with this next generation thrombectomy device," commented Joseph W. Kaufmann, Chief Executive Officer of Kensey Nash Corporation. "Our product development team has integrated several new features into the original ThromCat System. This version of the device offers more effective thrombus removal technology within an even easier to use system, thereby allowing physicians a faster and more effective method for removing coronary and peripheral thrombus," he concluded.

The ThromCat XT Thrombectomy Catheter System

The ThromCat XT System is based upon the same design principles as the original ThromCat product, which utilizes a high-speed rotary helix within a flexible atraumatic 7F extraction catheter to safely and effectively remove thrombus. The ThromCat XT extends the capability of this innovative first generation disposable device by incorporating an advanced extraction helix technology that improves the product's performance, particularly when used in more advanced thrombus. The ease-of-use of the ThromCat XT System is enhanced by further simplifying the setup procedure of the original device, resulting in an even shorter set up time. In addition, the device incorporates a new catheter jacket technology to allow use in more challenging anatomy, thereby extending the utility of this powerful and disposable device.

About Kensey Nash Corporation

Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the cardiovascular markets and the orthopaedic markets of sports medicine, spine, and extremities. Most of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of resorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also developed and commercialized a series of innovative endovascular products and completed the sale of these product lines to The Spectranetics Corporation in May 2008. Although the Company sold this portfolio of products to Spectranetics, the Company still participates directly in the future success of these products through a Manufacturing and Licensing Agreement and a Development and Regulatory Services Agreement. The Company is known as a pioneer in the field of biomaterials and arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.

Cautionary Note for Forward-Looking Statements

This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would", "forecast," "believe," or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties, and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, current economic conditions, foreign currency fluctuations, risks associated with the Company's continued research and development efforts with respect to the endovascular products (including the risk that those efforts will not be successful and that some of the associated milestone payments will not be received), Spectranetics' success in selling the QuickCat, ThromCat and SafeCross products, the Company's success in distributing its products into the marketplace, the Company's dependence on major customers and partners (St. Jude Medical, Arthrex, Orthovita and Spectranetics) and their success in selling Kensey Nash related products in the marketplace, the impact of product recalls and other manufacturing issues, the Company's success in its research and development efforts in its cartilage repair and extracellular matrix technologies programs and competition from other technologies, among other important risks. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thrombectomy Device Market to Approach $300 Million by 2013, According to Millennium Research Group
2. Thrombectomy Device Market to Approach $900 Million by 2013, According to Millennium Research Group
3. NeuroTherm Completes Acquisition of the Micron Epidural Catheter
4. Frost & Sullivan: Momentum Mounting for Catheter Ablation Technologies in Treatment of Atrial Fibrillation
5. Catheter Ablation Effective in Treating Atrial Fibrillation
6. Simulation training improves skills for catheter insertion
7. Expert consensus on catheter ablation of ventricular arrhythmias
8. Heating heart with catheter better than drugs for common heart rhythm disorder
9. Telesso Technologies wins Popular Science Invention Award for its novel peripheral IV catheter
10. Telesso initiates post-market head-to-head peripheral IV catheter study
11. Drug-Coated Sponges May Limit Catheter Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Gevir, a ... deer antler velvet, announced its products are coming soon to Amazon.com, the world’s largest ... Shelley Thomson as a means to develop an effective natural treatment for Shelley’s Multiple ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing a ... have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can be ... are free from the shame, stigma, and harmful labeling believed to prevent ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... N.J. (PRWEB) , ... February 22, 2017 , ... ... a one-size-fits-all approach, leads to fewer trips the emergency room, fewer hospital admissions, ... The American Journal of Managed Care® (AJMC®) finds. The study can be found ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, ... or not filling a prescription because they could not afford to pay for ... medications were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... -- a condition where an organ of the ... weak abdominal wall. Hernia is classified into five ... hernia, umbilical hernia, and other (hiatal hernia and ... performed using a mesh, made-up of biological or ... the available options, open tension-free repair procedures and ...
(Date:2/22/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), today announced ... ended December 31, 2016. ... This news release should be read ... discussion and analysis for the years ended December 31, 2016 ... available at www.sedar.com and on the Company,s website ...
(Date:2/22/2017)... Feb. 22, 2017 astic drugs develop from ... antineoplastic drug aiming at functions at multiple links. Research ... a new stage. Download the full report: ... nearly four million cases of new tumors in ... population, environmental pollution caused by industrialization and lifestyles changed ...
Breaking Medicine Technology: